Clinical trials in Hamburg – page 12

1 128 clinical trials in Hamburg, Germany across 19 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Hamburg at a glance

1 128

clinical trials

Research sites19

Quick filters

1 128 trials in Hamburg

Open in trial search

Obstructive sleep apnoea syndrome

Recruiting

Study of zenagamtide for weight loss and sleep improvement in patients with obesity and obstructive sleep apnea using positive airway pressure therapy

Investigational

Study of zenagamtide for weight loss and sleep improvement in patients with obesity and obstructive sleep apnea using positive airway pressure therapy

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:Novo Nordisk A/S

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

Registered drugNo placebo

A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Pfizer Inc.

Contact Research Centre

Bile duct cancer

Recruiting

A study of rilvegostomig, cisplatin, and gemcitabine compared to durvalumab and a drug combination for adults with advanced biliary tract cancer

Registered drugNo placebo

A study of rilvegostomig, cisplatin, and gemcitabine compared to durvalumab and a drug combination for adults with advanced biliary tract cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cisplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Acute kidney injury+2

Recruiting

Effect of sodium hydrogen carbonate on kidney health in critically ill patients with metabolic acidosis and acute kidney injury

Registered drugNo placebo

Effect of sodium hydrogen carbonate on kidney health in critically ill patients with metabolic acidosis and acute kidney injury

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:MALIC ACID
Sponsor:Universitaet Muenster

Contact Research Centre

Glioma

Recruiting

A study of ulixertinib, tovorafenib, and vinblastine sulfate for children with progressive, relapsed, or refractory low-grade glioma

Registered drugNo placebo

A study of ulixertinib, tovorafenib, and vinblastine sulfate for children with progressive, relapsed, or refractory low-grade glioma

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Tovorafenib
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Breast cancer+4

Recruiting

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Elacestrant
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Interstitial lung disease+1

Recruiting

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Treprostinil
Sponsor:Liquidia Technologies Inc.

Contact Research Centre

Gastric cancer+2

Recruiting

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Asthma

Recruiting

Comparison of CHF5993 (glycopyrronium bromide, formoterol fumarate dihydrate, and beclometasone dipropionate) and a drug combination for patients with mild to moderate asthma

Registered drugNo placebo

Comparison of CHF5993 (glycopyrronium bromide, formoterol fumarate dihydrate, and beclometasone dipropionate) and a drug combination for patients with mild to moderate asthma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Placebo
Sponsor:Chiesi Farmaceutici S.p.A.

Contact Research Centre

Hormone-refractory prostate cancer

Recruiting

A study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

A study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Janssen Cilag International

Contact Research Centre

Hormone-refractory prostate cancer+1

Recruiting

A study evaluating the efficacy and safety of inavolisib and enzalutamide in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

A study evaluating the efficacy and safety of inavolisib and enzalutamide in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Hamburg

What the registry says about research in the country

01 Oncology Research

Current clinical trials focusing on innovative treatments for metastatic prostate cancer, colorectal cancer, and breast cancer. Studies are evaluating new therapeutic combinations and targeted approaches for improved patient outcomes.

Advanced cancer therapies
Immunotherapy combinations
Treatment resistance strategies

02 Infectious Disease Prevention

Comprehensive vaccine development programs targeting respiratory syncytial virus, cytomegalovirus, and meningococcal infections. Research focuses on both adult and pediatric populations.

Vaccine immunogenicity
Long-term protection
Novel vaccine platforms

03 Neurological Conditions

Groundbreaking research in treating acute cerebral ischemic stroke with innovative therapies. Studies are evaluating functional outcomes and safety profiles of new therapeutic agents.

Stroke treatment
Neuroprotective strategies
Recovery outcomes

04 Women's Health

Clinical investigations addressing vaginal atrophy and contraceptive technologies. Research includes novel delivery systems and hormone-based treatments for postmenopausal conditions.

Reproductive health
Hormone therapy
Novel delivery systems

Back to Germany All countries